Vabilo na predavanje Prof. dr. Stephena Mingerja: Uporaba matičnih celic je nova paradigma zdravljenja in že spremenja način obravnavanja pacientov
Educell in Nacionalni inštitut za biologijo vabita na strokovno predavanje svetovno priznanega strokovnjaka za celične terapije in pred leti kandidata za Nobelovo nagrado:
Prof. dr. Stephena Mingerja
Uporaba matičnih celic je nova paradigma zdravljenja in že spremenja način obravnavanja pacientov
Predavanje bo v torek, 20 decembra 2016 ob 12.00 uri na Naconalnem inštitutu za biologijo, predavalnica B2, Večna pot 111, 1000 Ljubljana.
Originalen naslov predavanja, ki bo v angleškem jeziku je:
Blue Skies Innovation in Healthcare - the Future of Medicine.
"This talk will focus on current technologies in cellular therapy and regenerative medicine for a myriad of human disorders. However there are a number of convergent new technologies that will fundamentally change human healthcare in the near term and beyond that will have profound implications for health, aging, regeneration/rejuvenation and our conception of what is being human is or could be."
Več informacij in prijave:
Helena Končar, NIB
Tel.: 059 232 702
Dr Stephen Minger was appointed the Global Director for Research and Development for Cell Technologies at GE Healthcare in September 2009. Stephen received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine in New York City. After post-doctoral work in central nervous system gene therapy, neural transplantation and neural stem cell biology at UCSD with Professor Fred "Rusty" Gage, he moved to the UK in 1996 and was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998. He was appointed a Senior Lecturer in Stem Cell Biology in 2005 and was the Director of the Stem Cell Biology Laboratory from 2002 until joining GE Healthcare in 2009.
Over the past 20+ years, Stephen's research group has been at the forefront of human stem cell research. In 2002, his research team was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human embryonic stem (hES) cells and his group was the first to deposit a human ES cell line into the UK Stem Cell Bank. Stephen was also one of the first two groups in the UK to be granted a research license by the HFEA in 2008 to pursue Somatic Cell Nuclear Transfer (SCNT) to generate "hybrid human embryos" for fundamental research into genetic forms of neurodegenerative conditions. He was actively involved with the UK Department of Health and with the Minister for Public Health in the consultation with both Houses of Parliament that led to the passage of the Human Embryo Bill of 2009 and the inclusion of new forms of animal-human embryos within primary legislation.
Stephen was the Stem Cell Expert and a Member of the UK Gene Therapy Advisory Committee (GTAC) at the Department of Health from 2006-2012 and was the Focal Point for Regenerative Medicine, Drug Discovery and Modernisation of Traditional Chinese Medicine in China for the UK Department of Business, Innovation and Skills from 2006-2009. He has been an external consultant and reviewer to the European Commission Framework Programmes (FP6, FP7 and Horizon 2020) since 2003 to promote European-wide biomedical research, a member of the Grants Working Group of the California Institute of Regenerative Medicine since 2004, and is a member of the Board of Directors of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM).
In the summer of 2013, Stephen was appointed Chief Scientist for Cellular Sciences, GE Healthcare Life Sciences, and was responsible for long-term global research strategy for technology development in cell therapy, regenerative medicine, cellular technologies, in vivo diagnostic imaging and precision diagnostics. He left full-time employment with GE in Feb 2015 but is still a part-time Senior Consultant in Cellular Sciences and Regenerative for GE Healthcare Life Sciences. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community.